Clinical Trial: To Explore the Optimal Therapeutic Window for Imatinib in the Adjuvant Treatment of Intermediate and High-risk Gastrointestinal Stromal Tumors

U.S., May 30 -- ClinicalTrials.gov registry received information related to the study (NCT07614841) titled 'To Explore the Optimal Therapeutic Window for Imatinib in the Adjuvant Treatment of Intermediate and High-risk Gastrointestinal Stromal Tumors' on May 22.

Brief Summary: The goal of this observational study is to explore the quantitative relationship between in vivo exposure and efficacy, and the relationship between in vivo exposure and the risk of adverse reactions after adjuvant treatment of imatinib in patients with intermediate and high-risk GIST in the real world, so as to determine the optimal treatment window for imatinib .

Study Start Date: Jan. 01, 2015

Study Type: OBSERVATIONAL

Condition: Gastrointestinal Stromal Tumor...